NEW YORK (GenomeWeb News) – Agilent Technologies today announced a deal with BioDiscovery allowing that firm's customers access to Agilent SureFISH probes directly from BioDiscovery's Nexus software.

The deal allows researchers who use different cytogenetic microarray platforms to now quickly identify aberrations with Nexus and to immediately identify and link to available oligonucleotide-based fluorescent in situ hybridization probes for follow-up studies, Agilent said.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.